Appearance of anti-MDA5 antibody-positive dermatomyositis after COVID-19 vaccination.
Mod Rheumatol Case Rep
; 7(1): 108-112, 2023 01 03.
Article
em En
| MEDLINE
| ID: mdl-35950798
ABSTRACT
The direct causes of dermatomyositis, a common autoimmune disease, have not yet been accurately identified, but several studies have linked this condition to various patient-associated and environmental factors, such as viral infections and area of residence. In the present report, we describe our experience with a patient presenting with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis, which developed after vaccination against coronavirus disease 2019 (COVID-19). This patient was simultaneously diagnosed with anti-glutamic acid decarboxylase antibody-positive slowly progressive insulin-dependent diabetes (SPIDDM); her human leucocyte antigen test revealed that she expressed the DRB1*0405 allele. This is important as this genotype is known to increase susceptibility to both anti-MDA5 antibody-positive dermatomyositis and type I diabetes. To the best of our knowledge, this is the first case of dermatomyositis complicated by SPIDDM identified after COVID-19 vaccination against COVID-19 and presenting with an underlying susceptible genotype. The patient's genetic predisposition may also be important for the development of autoimmune disease after COVID-19 vaccination.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Autoimunes
/
Doenças Pulmonares Intersticiais
/
Dermatomiosite
/
Diabetes Mellitus
/
Vacinas contra COVID-19
/
COVID-19
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article